Ocugen | 8-K: Ocugen Announces U.S. Food and Drug Administration Approval of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.